Goodwin advised Disc Medicine (NASDAQ: IRON) on its upsized underwritten offering of (i) 4,533,182 shares of its common stock at a public offering price of $55.00 per share, which included the full exercise by the underwriters of their option to purchase an additional 615,000 shares, and (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase 181,818 shares of common stock at a public offering price of $54.9999 per pre-funded warrant, which represents the public offering price of each share of common stock, less the $0.0001 per share exercise price for each pre-funded warrant. The aggregate gross proceeds to Disc from this offering were approximately $259.3 million, before deducting underwriting discounts and commissions and other offering expenses, excluding the exercise of any pre-funded warrants. Disc granted the underwriters a 30-day option to purchase up to an additional shares of its common stock at the public offering price, which was exercised in connection with the closing of the offering.
Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. Disc is building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.
The Goodwin team was led by Bill Collins, Adam Johnson, Alicia Tschirhart, Eunice Chang and Tris Cox (Corporate); Susan Lee and Sukrti Thonse (FDA Regulatory); Janet Andolina, Kyle Pine and Garret Gaughan (Tax).
For more information on the deal, please read the press release.
Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. Disc is building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.
The Goodwin team was led by Bill Collins, Adam Johnson, Alicia Tschirhart, Eunice Chang and Tris Cox (Corporate); Susan Lee and Sukrti Thonse (FDA Regulatory); Janet Andolina, Kyle Pine and Garret Gaughan (Tax).
For more information on the deal, please read the press release.